RNXT RenovoRx

RNXT: kumpleto na ang enrollment ng Phase 3 TIGeR-PaC; topline data sa H2 2027

Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine via RenovoCath reached full enrollment. Trial completion expected in H1 2027 after 86 events; topline data readout now guided for H2 2027. 15 trial sites are positioned to transition to commercial RenovoCath use.

Itatampok ng RenovoRx ang TAMP Platform sa JonesTrading KOL Webinar tungkol sa pancreatic cancer

The company announced participation in a JonesTrading virtual KOL webinar on August 13, 2026 at 1:30 p.m. ET. The webinar will cover the TAMP platform, RenovoCath device, and the ongoing Phase III TIGeR-PaC trial. RenovoRx also noted full TIGeR-PaC enrollment expected soon and final data readout in mid to late 2027.

RenovoRx: Nagbigay ang FDA ng ODD para sa oxaliplatin sa pancreatic cancer

Nagbigay ang FDA ng Orphan Drug Designation para sa oxaliplatin sa pancreatic cancer, na nagbibigay ng pitong taon ng market exclusivity kapag naaprubahan, 25% tax credit sa mga kwalipikadong gastos sa klinikal, at waiver ng mga bayarin sa aplikasyon ng FDA. Ito ang ikatlong ODD ng RenovoRx sa kabuuan at pangalawa sa pancreatic cancer, na nagpapalawak sa pipeline lampas sa kasalukuyang IAG designation nito.

RenovoRx: nasa tamang landas ang enrollment ng Phase 3 TIGeR-PaC para sa kalagitnaan ng 2026

The company updated that the Phase 3 TIGeR-PaC trial has randomized 104 patients with 72 events observed and remains on track for full enrollment of 114 patients by mid-2026. Final data are now guided for 2027, and 17 trial centers are expected to transition to commercial RenovoCath customers in H2 2026.